Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jun 26, 2017
Tazemetostat and Atezolizumab to be Evaluated as New Combination in Study of Non-Small Cell Lung Cancer as Part of Genentech's MORPHEUS Cancer Immunotherapy Platform Further Expands Tazemetostat Solid Tumor Program CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company cre...
Jun 21, 2017
CAMBRIDGE, Mass., June 21, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tazemetostat, the company's first-in-class EZH2 inhibitor, for the treatment of pat...
Jun 14, 2017
Data Presented During Plenary Session at International Conference on Malignant Lymphoma Conference Call to be Held Today at 10:30 a.m. ET CAMBRIDGE, Mass., June 14, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced positive interim efficacy ...
May 18, 2017
Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be Presented at ASCO Conference Call to be Held Today, May 18 at 8:30 a.m. ET CAMBRIDGE, Mass., May 18, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (N...
May 8, 2017
Interim Phase 2 Data of Tazemetostat in Molecularly Defined Solid Tumors and NHL to be Presented at Scientific Meetings in June Conference Call on Interim Solid Tumor Data to be Held on May 18, 2017 Conference Call on Interim NHL Data to be Held on June 14, 2017 CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM)...
May 4, 2017
CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced it has earned a $10 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK's initiation of GLP toxicology studies for a first-in-class meth...
Apr 25, 2017
Interim Efficacy and Safety Data from Ongoing Phase 2 Study in Follicular Lymphoma and DLBCL Selected for Plenary Presentation at the International Conference on Malignant Lymphoma Management to Host Conference Call on June 14 at 10:30 a.m. ETCAMBRIDGE, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage bi...
Apr 20, 2017
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will release its first quarter 2017 financial results on Monday, May 8, 2017. Epizyme also announced that two posters on interim efficacy and safety...
Mar 29, 2017
CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that new preclinical data on tazemetostat, Epizyme's lead product candidate and first-in-class EZH2 inhibitor, along with other epigenetic target identification efforts, ...
Mar 9, 2017
Data from Tazemetostat Phase 2 Programs in NHL and Molecularly Defined Solid Tumors Planned for Medical Meetings in Second Quarter Conference Call to Be Held Today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic t...
Mar 9, 2017
CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert A. Copeland, Ph.D., will be retiring from Epizyme in the second quarter of 2017 to pursue advisory and oth...
Feb 27, 2017
CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and webcast at 8:30 a.m. ET on Thursday, March 9, 2017, to discuss its fourth quarter and full-year 2016 financial results and ...
Feb 7, 2017
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has elected industry veteran Kevin Conroy, chairman and chief executive officer of Exact Sciences (NASDAQ: EXAS), to its Board of Directors. "We are ...
Feb 2, 2017
CAMBRIDGE, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at the following investor conferences in February: Leerink Partners Global Healthcare Conference (fireside chat format) on Wednesday, Fe...
Jan 3, 2017
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore, chief executive officer of Epizyme, will present a company overview at the J.P. Morgan 35th Annual Healthcare Conference on Monday, January 9, 2017 a...
Nov 28, 2016
FDA Grants Tazemetostat Fast Track Designation for DLBCL with EZH2 Activating Mutations Company Focuses Phase 2 Solid Tumor Study on INI1-Negative Tumors and Expands Epithelioid Sarcoma Cohort CAMBRIDGE, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigeneti...
Nov 21, 2016
CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert A. Copeland, Ph.D., has been named a fellow of the American Association for the Advancement of Science (AAA...
Nov 3, 2016
Robust Clinical Program Underway for Tazemetostat in Multiple Cancer Indications and Treatment Settings as Both Monotherapy and Combination Agent Conference Call to Be Held Today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating nove...
Oct 31, 2016
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it has entered into two Cooperative Research and Development Agreements (CRADAs) with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (N...
Oct 27, 2016
CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and audio webcast on Thursday, November 3, 2016, at 8:30 a.m. Eastern Time to report recent company highlights and third quarte...
Sep 29, 2016
CAMBRIDGE, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode to the position of vice president of regulatory affairs and quality assurance. Strode will report to Epizyme's ...
Sep 21, 2016
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement with Foundation Medicine, Inc. to support patient identification and enrollment for Epizyme's ongoing Phase...
Sep 15, 2016
CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK's initiation of patient dosing in a Phase 1 clinical trial o...
Sep 1, 2016
CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at three investor conferences in September: Citi's 11th Annual Biotech Conference on Thursday, September 8 at 8:00 a.m. ET in Boston;Ro...
Aug 11, 2016
CAMBRIDGE, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the first patient has been dosed in the Company's global phase 2 study evaluating tazemetostat, a first-in-class EZH2 inhibitor, for the treatment of adults with meso...
Aug 8, 2016
Company Updates Financial Guidance Extending Runway into At Least Second Quarter of 2018 Conference Call to Be Held Today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today reported financial results ...
Aug 1, 2016
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced today that management will host a conference call and audio webcast on Monday, August 8, 2016, at 8:30 a.m. Eastern Time to report business highlights and progress against the c...
Jun 22, 2016
Clinical trial to evaluate Epizyme's clinical-stage EZH2 inhibitor in combination with anti-PD-L1 cancer immunotherapy CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people w...
Jun 19, 2016
Tazemetostat demonstrates favorable safety profile consistent with prior clinical experience Four of five cohorts have now surpassed futility, including follicular lymphoma with EZH2 mutation; responses observed in all patient cohorts CAMBRIDGE, Mass.--(BUSINESS WIRE...
May 12, 2016
CAMBRIDGE--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that data from four abstracts from the Company's clinical development program in support of tazemetostat for use in non-Hodgkin ...
May 9, 2016
Presentation of early safety and efficacy data from the tazemetostat phase 2 non-Hodgkin lymphoma study planned for ASH Meeting on Lymphoma Biology Conference call to be held today at 8:00 a.m. Eastern Time CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme,...
May 9, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has entered into a collaboration agreement with the Lymphoma Study Association (LYSA) to investigate the combination of ...
May 6, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as Chief Operating ...
May 4, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for tazemetostat...
May 2, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today that management will host a conference call and live audio webcast on Monday, May 9, 2016, at 8:00 a.m. Eastern Time to ...
Apr 25, 2016
Susan Graf joins as Chief Business Officer Jeannie Chu joined as Vice President of Program and Portfolio Management Michael Boretti, Ph.D. joined as Vice President of Business Development CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epi...
Apr 18, 2016
Data support the ability to administer tazemetostat with or without food Data demonstrate that tazemetostat is only a weak inducer of CYP3A-mediated metabolism NEW ORLEANS--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage ...
Mar 17, 2016
Five posters comprising preclinical and clinical investigations of tazemetostat to be presented at American Association for Cancer Research Annual Meeting 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel ...
Mar 9, 2016
Company reiterates financial runway guidance through at least the end of 2017 and through major research and development milestones Conference call to be held today at 8:00am E.T. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical s...
Mar 9, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc., (NASDAQ:EPZM) a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced its corporate vision and strategy through 2020. During the next five years, Epizyme will focus on four transformative activities...
Mar 2, 2016
Conference Call to be Held at 8:00 a.m. E.T. on March 9 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today it will host a conference call on Wednesday, March ...
Feb 8, 2016
- U.S. study sites enrolling adult patients with genetically-defined solid tumors, including malignant rhabdoid tumors, in registration-supporting phase 2 study - U.S. study sites enrolling pediatric patients with genetically-defined solid tumors, including malignant rhabdoid tumors, in phase 1 do...
Feb 1, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the Company will participate in four investor conferences in February: 2016 Canaccord Ge...
Jan 12, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the closing of its public offering of 15,333,334 shares of its common stock at a price of $9.00 per share before underwriting ...
Jan 6, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 13,333,334 shares of its common stock at a price of $9.00 per share before underwriting ...
Jan 5, 2016
CAMBRIDGE, Mass--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that it intends to offer and sell up to $120,000,000 of shares of its common stock in an underwritten public offering. Epizyme int...
Dec 30, 2015
U.S. study sites now enrolling adults in registration-supporting phase 2 study U.S. study sites now enrolling pediatric patients in phase 1 dose escalation study CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage bi...
Dec 28, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced the U.S. Food and Drug Administration's (FDA) Division of Hematology Products has accepted the company's investigational new drug (IN...
Dec 7, 2015
Objective responses seen in nine of 16 (56 percent) response-evaluable patients with either relapsed or refractory Non-Hodgkin Lymphoma Four responders remain on study at data cutoff; durable and ongoing objective responses seen up to 19 months Recommende...
Nov 24, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, will participate in the Piper Jaffray 27th Annual Healthcare Conference at the Lotte Palace Hotel in New York on Tuesday, December 1 at ...
Nov 9, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today reported business highlights and operating and financial results for the third quarter of 2015. "Epizyme is well-posit...
Nov 5, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that data from the ongoing phase 1 study of tazemetostat (EPZ-6438) will be presented during the American Society of Hematology Meeti...
Nov 4, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, will present data from 11 accepted abstracts on the role of histone methyltransferase (HMT) inhibition in human cancers at the AACR-NCI-EORTC Intern...
Nov 2, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today it will host a conference call and live audio webcast on Monday, November 9, 2015 at 8:00 a.m. ET to report third quarter 2015 fi...
Sep 26, 2015
Partial response by RECIST criteria observed in heavily pretreated SMARCA4-negative malignant rhabdoid tumor of the ovary (MRTO) with duration over six months Previously reported complete response in INI1-negative malignant rhabdoid tumor (MRT) continues at 65 weeks ...
Aug 31, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, will participate in four upcoming events in September: Citi 10th Annual Biotech Conference at the Mandarin...
Aug 24, 2015
Phase 2 study in adults and phase 1 study in pediatric patients with INI1-negative tumors or synovial sarcoma to begin in the second half of 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel ...
Aug 6, 2015
Initiated 5-arm phase 2 study of tazemetostat in NHL Presenting updated data from solid tumor patients in the ongoing phase 1 study of tazemetostat at ESMO's European Cancer Congress in Vienna, Austria on September 26, 2015 As of June 30, 2015, Epizyme had cash and ...
Aug 5, 2015
-- Outgoing President and CEO Robert Gould, Ph.D. will Continue to Serve as Member of Board of Directors -- -- Transition effective September 10, 2015 -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical research and...
Aug 4, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced its participation at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 1:55 p.m. ET at the Le Pa...
Jul 30, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today it will host a conference call and live audio webcast on Thursday, August 6, 2015 at 7:30 a.m. ET to report second quarter 2015 f...
Jul 9, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that it has dosed the first patient in the phase 2 trial of its lead clinical candidate, tazemetostat (EPZ-6438) in patients with re...
Jul 9, 2015
Collaboration to focus on three first-in-class preclinical epigenetic targets Epizyme to receive $10 million extension fee payment and up to $610 million in potential milestones Epizyme extends cash runway through at least the end of the second quarter of...
Jun 29, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from the phase 1 portion of its ongoing phase 1/2 study of tazemetostat will be presented during the European Canc...
Jun 20, 2015
Objective responses seen in nine of 15 evaluable relapsed non-Hodgkin lymphoma (NHL) patients; five responders remain on study First treated patient with an EZH2 mutant tumor achieved partial response and remains on study Phase 2 NHL trial now enrolling patients; pl...
Jun 15, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced its participation in two upcoming events in June: 13th International Conference on Malignant ...
Apr 30, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced its participation in two upcoming conferences in May: Mizuho Healthcare Corporate Access Day...
Apr 28, 2015
Reacquired global rights to EPZ-6438 from Eisai, gaining full control of development, manufacturing and commercialization outside of Japan Completed successful public offering of shares of common stock, raising $130.7 million before expenses, including the April exercise of ...
Apr 21, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that it will host a conference call and live audio webcast on Tuesday, April 28, 2015, at 4:30 PM ET to report first quarter 2015 fi...
Apr 20, 2015
- First example of a peptide-bound structure for CARM1 provides insights for pathway targeting - - First-in-class PRMT6 inhibitor demonstrates potency and selectivity - PHILADELPHIA--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical c...
Apr 20, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from the Phase 1 portion of the ongoing Phase 1/2 study of EPZ-6438 will be presented during the 13th ...
Apr 17, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised t...
Mar 18, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that data from its preclinical pipeline will be presented during the American Association for Cancer Research (AACR) Annual...
Mar 17, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 6,000,000 shares of its common stock at a price of $20.75 per share before underwriting ...
Mar 16, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that it intends to offer and sell up to 4,750,000 shares of its common stock in an underwritten public offering. Epizyme intends ...
Mar 12, 2015
Reacquired global rights to EPZ-6438 from Eisai, gaining full control of development, manufacturing and commercialization outside of Japan Data from ongoing Phase 1 dose escalation study of EPZ-6438 in B-cell non-Hodgkin lymphoma (NHL) and advanced solid tumors presented at ...
Mar 12, 2015
- Epizyme obtains global operational responsibility and exclusive worldwide commercial rights outside of Japan - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, an...
Mar 5, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, March 12, 2015, ...
Mar 3, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that updated data from the ongoing Phase 1 dose escalation study of EPZ-6438 (referred ...
Feb 27, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation at the Cowen and Company 35th Annual Health Care Conference on ...
Feb 5, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming conferences in February: ...
Feb 3, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew Singer will join the Company as Chief Financial Officer on February 9th. Mr. Singer ...
Jan 29, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Robert A. Copeland, Ph.D., has been named President of Research. Dr. Copeland, who was ...
Dec 8, 2014
Three objective responses: Two complete responses (CRs) in 54 mg/m2/day dose cohort and one partial response (PR) in 90 mg/m2/day dose cohort, as of October 6, 2014 data cut-off Additional biological activity observed: Resolution of cutaneous leukemia in two patients, leukemia cell dif...
Dec 8, 2014
Potent, selective and orally bioavailable inhibitor of PRMT5 First arginine methyltransferase (RMT) inhibitor to show in vitro and in vivo activity in pre-clinical models of mantle cell lymphoma (MCL) Displays robust anti-tumor activity as single agent in MCL ...
Dec 3, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a live audio webcast of its discussion of the Company's clinical prog...
Nov 19, 2014
Partial response or better seen in four of 10 evaluable patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including three of five evaluable patients with diffuse large B-cell lymphoma (DLBCL) Ongoing complete response observed in one DLBCL patient ...
Nov 6, 2014
Initial data from ongoing Phase 1 study of EPZ-6438 support expanded Phase 2 study in EZH2 mutant and wild type non-Hodgkin lymphoma (NHL), to initiate in 1Q15: More complete, updated dose escalation data to be featured in late-breaking oral presentation at EORTC-NCI-AACR Symposium on November 20th ...
Nov 6, 2014
Thirty-six patients were evaluable for safety and 28 patients were evaluable for efficacy across six dosing cohorts (12, 24, 36, 54, 80 and 90 mg/m2/day) as of July 15th data cut-off Adverse events were predominantly Grade 1 or Grade 2 in severity Complete responses...
Oct 30, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, November 6, ...
Oct 27, 2014
-- Chief Development Officer Peter Ho, M.D., Ph.D., will continue to oversee clinical development, as well as translational medicine and regulatory activities -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating inno...
Oct 23, 2014
-- Publication of patent applications for five additional HMT targets broadens intellectual property estate and demonstrates the breadth of Epizyme leadership in the field of histone methyltransferases (HMTs) -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a cli...
Oct 17, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today presented pre-clinical data on EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in m...
Oct 10, 2014
-- Oral presentation of data from Phase 1 clinical trial of DOT1L inhibitor EPZ-5676 in adults with MLL-r leukemia -- -- Oral presentation of pre-clinical data on first-in-class PRMT5 inhibitor in lymphoma models - -- Poster presentation on pharmacokinetic modeling in Phase 1 study...
Oct 1, 2014
--Late-breaking oral presentation will include data from the dose escalation portion of ongoing Phase 1/2 study in advanced solid tumors or B cell lymphomas-- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creati...
Sep 25, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming events in October: ...
Sep 15, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih...
Sep 2, 2014
-- Mr. Rhodes to serve as an advisor to Epizyme through the fourth quarter of 2014 -- -- Mr. Rhodes will be returning to venture capital -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovativ...
Aug 26, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in five upcoming conferences in September: ...
Aug 13, 2014
Presented pre-clinical data showing EPZ-6438 synergy with NHL standards of care and targeted therapies at American Society of Hematology (ASH) Meeting on Lymphoma Biology on August 12, 2014 Presented early clinical observations from first three cohorts (12 evaluable patients) of ongoin...
Aug 12, 2014
--In three dose cohorts completed to date: maximum tolerated dose (MTD) not reached; pharmacokinetics (PK) were dose-proportional; pharmacodynamic (PD) evidence of target inhibition was observed; objective responses were seen in two NHL patients -- -- Ongoing enrollment in dose cohorts 4 and 5 - ...
Jul 28, 2014
-- Company to present pre-clinical data and early clinical observations from Phase 1 study of EPZ-6438 (E7438) at ASH Lymphoma meeting on August 12, 2014 -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating ...
Jun 10, 2014
CAMBRIDGE, Mass., June 10, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that an abstract on EPZ-6438 has been accepted for oral presentation at the American Society of Hematology (ASH) Meeting...
May 28, 2014
CAMBRIDGE, Mass., May 28, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in June: Jefferies 2014 Global Health Care Conference in New Yo...
May 13, 2014
CAMBRIDGE, Mass., May 13, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced first quarter 2014 operating and financial results and updated 2014 guidance. "During the first quarter of 2014, E...
May 7, 2014
CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Tuesday, May 13, 2014, at 4:30 p.m. ET to report first quart...
May 7, 2014
CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a re...
May 1, 2014
CAMBRIDGE, Mass., May 1, 2014 /PRNewswire-USNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in May: Cancer Advance NY at Apella Event Space in Ne...
Apr 30, 2014
CAMBRIDGE, Mass., April 30, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew R. Allen, M.D., Ph.D., co-founder and Executive Vice President of Clinical and Pre-Clinical Development and...
Apr 24, 2014
CAMBRIDGE, Mass., April 24, 2014 /PRNewswire-USNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted a notice of allowance for U.S. Patent Application No. ...
Apr 22, 2014
CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate milestone for the third of the three histone methyltransferase (HMT) targets in t...
Apr 8, 2014
CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identificatio...
Feb 28, 2014
CAMBRIDGE, Mass., Feb. 28, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation at the Cowen and Company 34th Annual Health Care Conference. Cowen and Company 34th Annual ...
Feb 27, 2014
CAMBRIDGE, Mass., Feb. 27, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced 2013 operating and financial results and provided 2014 guidance. "2013 was a transformative year for Epizyme, wit...
Feb 27, 2014
CAMBRIDGE, Mass., Feb. 27, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate selection milestone for one of the histone methyltransferase (HMT) targets in the ...
Feb 21, 2014
CAMBRIDGE, Mass., Feb. 21, 2014 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data from preclinical studies of the company's clinical candidate EPZ-6438 (E7438), a potent and sele...
Feb 19, 2014
CAMBRIDGE, Mass., Feb. 19, 2014 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, February 27, 2014, at 4:30 p.m. ET to report fou...
Feb 11, 2014
CAMBRIDGE, Mass., Feb. 11, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that, following the initial closing of its recent public offering o...
Feb 7, 2014
CAMBRIDGE, Mass., Feb. 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced it will present a company overview at the following conferences in February: 16th Annual BIO CEO & Investor Co...
Feb 5, 2014
CAMBRIDGE, Mass., Feb. 5, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced the pricing of its underwritten public offering of 4,492,679 shares ...
Feb 3, 2014
CAMBRIDGE, Mass., Feb. 3, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has commenced an underwritten public offering of 4,192,679 s...
Jan 6, 2014
— Epizyme Also Achieves $4 Million Development Candidate Milestone with GSK — — 2013 End-of-Year Cash Guidance Increased — — Five Clinical Proof of Concept Programs Planned in 2014 — CAMBRIDGE, Mass., Jan. 6, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharm...
Jan 6, 2014
CAMBRIDGE, Mass., Jan. 6, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its CEO, Robert J. Gould, will present at the 32nd Annual J.P. Morgan Healthcare Conference. The presentation is schedule...
Dec 20, 2013
CAMBRIDGE, Mass., Dec. 20, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective befo...
Dec 2, 2013
CAMBRIDGE, Mass., Dec. 2, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in December: Piper Jaffray 25th Annual Healthcare Conference at...
Nov 14, 2013
CAMBRIDGE, Mass., Nov. 14, 2013 /PRNewswire/ -- Four dose cohorts (12, 24, 36 and 54 mg/m2/day) completed (16 patients, 8 with acute leukemia with MLL-r) with 21-day on/7-day off administration schedule Observations to date include: No dose-limiting toxicities; maximum tolerated dose (MTD) not reached Treatment effects, c...
Nov 7, 2013
CAMBRIDGE, Mass., Nov. 7, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, will present pre-clinical data on EPZ-5676 and EPZ-6438, the Company's DOT1L and EZH2 clinical programs, at the 55th Annual Meeting of th...
Oct 29, 2013
CAMBRIDGE, Mass., Oct. 29, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in November: Cancer Epigenetics Conference, one of two paralle...
Oct 22, 2013
CAMBRIDGE, Mass., Oct. 22, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today provided a corporate update and reported financial results for the quarter ended September 30, 2013. "2013 has been an impo...
Oct 15, 2013
CAMBRIDGE, Mass., Oct. 15, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the Company will host a conference call and live audio webcast on Tuesday, October 22, 2013, at 4:30 p.m. EDT to re...
Sep 30, 2013
CAMBRIDGE, Mass., Sept. 30, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in October: Leerink Swann Rare Disease Roundtable at Le Parke...
Sep 3, 2013
CAMBRIDGE, Mass., Sept. 3, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Applicatio...
Aug 28, 2013
CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in upcoming September conferences. Citi 8th Annual Biotech Day at the Mandarin Oriental Hot...
Aug 16, 2013
Small Molecule Inhibitor of the DOT1L Histone Methyltransferase (HMT) designated for Acute Leukemias with MLL Rearrangements (MLL-r) CAMBRIDGE, Mass., Aug. 16, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with geneti...
Aug 6, 2013
CAMBRIDGE, Mass., Aug. 6, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation at the Wedbush Securities Life Sciences Management Access Conference. Wedbush Securities Lif...
Jul 31, 2013
CAMBRIDGE, Mass., July 31, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today provided a corporate update and reported financial results for the second quarter ended June 30, 2013. "The second quarter ...
Jul 24, 2013
CAMBRIDGE, Mass., July 24, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the Company will host a conference call and live audio webcast on Wednesday, July 31st, at 4:30 p.m. EDT to report ...
Jul 3, 2013
CAMBRIDGE, Mass., July 3, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Jason P. Rhodes, Executive Vice President and Chief Financial Officer, has been named President of Epizyme. Mr. Rhod...
Jul 1, 2013
CAMBRIDGE, Mass., July 1, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the Company has been added to the Russell 2000®, Russell 3000® and Russell Global® Indexes...
Jun 27, 2013
CAMBRIDGE, Mass., June 27, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming conferences. 2013 JMP Securities Healthcare Conference at The St. Regis i...
Jun 26, 2013
CAMBRIDGE, Mass., June 26, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data on the company's clinical candidate EPZ-5676, a potent and selective small-molecule inhibitor of...
Jun 13, 2013
CAMBRIDGE, Mass., June 13, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled in a Phase 1/2 clinical trial of EPZ-6438 (E7438). The trial is designed to ass...
Jun 5, 2013
CAMBRIDGE, Mass., June 5, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM) today announced the closing of its initial public offering of 5,913,300 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts, including 771,300 shares of common stock issued upon the exercise in full by the underwriters of...
May 30, 2013
CAMBRIDGE, Mass., May 30, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc. today announced the pricing of its initial public offering of 5,142,000 shares of its common stock at a public offering price of $15.00 per share, before underwriti...
Apr 26, 2013
Cambridge, Mass. - April 26, 2013 Epizyme, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not ...
Apr 18, 2013
Cambridge, Mass. - April 18, 2013 - Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has signed an agreement with Abbott, a global healthcare company, to develop a molecular companion diagnostic test for use with E...
Mar 22, 2013
Feb 4, 2013
Jan 7, 2013
Jan 3, 2013
Nov 29, 2012
Nov 20, 2012
Oct 29, 2012
Oct 3, 2012
Sep 30, 2012
Sep 28, 2012
Sep 5, 2012
Sep 4, 2012
Aug 1, 2012
Jul 16, 2012
Jun 7, 2012
Jun 1, 2012
May 16, 2012
May 1, 2012
Apr 26, 2012
Apr 10, 2012
Cambridge, MA, April 10, 2012 - ...
Mar 13, 2012
White Plains, NY and Cambridge, MA, March 13, 2012 - The Leukemia & Lymphoma Society (LLS) and Epizyme announced today that they have achieved a pre-clinical milestone in their partnership to develop Epizyme’s ...
Jan 10, 2012
Cambridge, MA – January 10, 2012 – Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced the achievement of a pre-clinical milestone in its alliance with Eisai Co., Ltd., triggering a $4 million milestone payment. ...
Nov 30, 2011
Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, to...
Nov 9, 2011
Cambridge, MA, November 9, 2011 - Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced that Mr. Jason Rhodes, Executive Vice President and Chief Business Officer, will present at the Lazard Capital Markets 8...
Oct 14, 2011
Cambridge, MA - October 14, 2011 – Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced the achievement of pre-clinical milestones in its alliance with GlaxoSmithKline (GSK), triggering $4 million in mil...
Sep 6, 2011
Cambridge, MA – September 6, 2011 - Epizyme, Inc., a leader in the discovery and development of personalized therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics, announced today that it has been selected by the editors of FierceBiotech a...
Aug 31, 2011
Cambridge, MA, August 31, 2011 – Epizyme, Inc., a company leading the discovery and development of targeted therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in three upcoming conferences being held the first week of September...
Jul 11, 2011
Cambridge, Massachusetts, July 11, 2011– Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rea...
Jun 23, 2011
White Plains, NY and Cambridge, MA, June 23, 2011 - The Leukemia & Lymphoma Society (LLS) and Epizyme announced today that they will jointly support pre-clinical and Phase 1 development of Epizyme’s DOT1L-targeted histone methyltransferase inhibitor (HMTi) for Mixed Lineage Le...
Apr 27, 2011
Cambridge, MA, April 27, 2011 - Epizyme, Inc., a leader in the creation of personalized therapeutics based on breakthrough discoveries in the field of epigenetics, announced today the company has been identified as the #1 company nationwide in The Scientist's ...
Mar 10, 2011
Cambridge, MA, March 10, 2011 - Epizyme, Inc. announced today a worldwide partnership with Eisai Co., Ltd., Tokyo, Japan to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients. Under the terms of the agreement, Ep...
Feb 10, 2011
Cambridge, MA, February 10, 2011 - Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in three upcoming conferences being held during February. ...
Jan 10, 2011
Cambridge, MA, January 10, 2011 – Epizyme today announced a worldwide strategic alliance with GlaxoSmithKline (GSK) to discover, develop, and market novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases. ...
Jan 6, 2011
NORWALK, Conn. – January 6, 2011 - The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of...
Nov 23, 2010
Cambridge, MA, November 23, 2010 - Epizyme, Inc., a company creating personalized therapeutics based on breakthrough discoveries in the field of epigenetics, announced that data related to the Company’s programs will be the subject of multiple oral presentations at the 52nd American Society of Hematology (ASH) Annual Mee...
Nov 15, 2010
Cambridge, MA, November 15, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced the publication of breakthrough new research in the Proceedings of the National Academy of Sciences (USA). The discovery, center...
Nov 3, 2010
Cambridge, MA, November 3, 2010 - Epizyme, Inc., a company leading the discovery and development of first‐in‐class, targeted cancer therapeutics against epigenetic targets, today announced that it has been awarded $733,437 in grants under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grants are for t...
Jul 16, 2010
Cambridge, MA, July 16, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme...
May 14, 2010
Cambridge, MA, May 14, 2010 - Epizyme, Inc. announced today the appointment of Mikel Moyer, Ph.D., as Vice President of Molecular Discovery. He joins Epizyme from the Broad Institute, where he was Director of Medicinal Chemistry in the Stanley Center for Psychiatric Research. Prior to the Broad, Dr. Moyer held leadership posi...
Mar 24, 2010
Cambridge, MA, March 24, 2010 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceuticals, announced today the appointment of Robert Gould, Ph.D. as Chief Executive Officer and of Jason Rhodes as Executive Vice President and Chief Business Officer. Dr. Gould h...
Dec 8, 2009
Cambridge, MA, December 8, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M. Epizyme initially announced a $32M ro...
Oct 20, 2009
Cambridge, MA, October 20, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today that Dr. Hoyoung Huh, President and CEO of BiPar Sciences, Inc., was appointed Epizyme's Chairman of the Board of Directors. Epizyme recently ann...
Oct 7, 2009
Cambridge, MA, October 7, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the closing of a $32 million Series B financing led by new investor Bay City Capital (BCC). Joining BCC as new investors are Amgen Ventures and As...
Sep 9, 2009
Cambridge, MA, Sepetember 9, 2009 - A paper underscoring the importance of protein methyltransferases (PMTs) in drug discovery is published in the September 2009 online issue of NATURE REVIEWS DRUG DISCOVERY. Scientists Dr. Robert A. Copeland and Dr. Victoria M. Richon from Epizyme, Inc. in their paper entitled "Protein methyl...
Page:
...
Next Last
 
= add release to Briefcase